Results 11 to 20 of about 811,174 (190)

The Development of BTK Inhibitors: A Five-Year Update

open access: yesMolecules, 2021
Bruton’s tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders.
Bruno Tasso   +3 more
doaj   +2 more sources

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

open access: yeseLife
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph   +7 more
doaj   +2 more sources

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

open access: yesThe Journal of Clinical Investigation, 2023
Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed
Vivian Changying Jiang   +20 more
doaj   +2 more sources

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

open access: yeseJHaem, 2021
All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK‐1026.
Bibian M.E. Tullemans   +13 more
doaj   +2 more sources

Phylogeny of Tec Family Kinases: Identification of a Pre-Metazoan Origin of Btk, Bmx, Itk, Tec, Txk and the Btk Regulator SH3BP5 [PDF]

open access: yes, 2008
It is generally considered mammals and birds have five Tec family kinases (TFKs): Btk, Bmx (also known as Etk), Itk, Tec, and Txk (also known as Rlk). Here, we discuss the domains and their functions and regulation in TFKs.
Ortutay, Csaba   +3 more
core   +2 more sources

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

open access: yeseLife, 2020
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph   +5 more
doaj   +1 more source

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases

open access: yesPharmaceuticals, 2023
Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi   +8 more
doaj   +1 more source

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors [PDF]

open access: yes, 2021
Low-molecular weight chemical compounds have a longstanding history as drugs. Target specificity and binding efficiency represent major obstacles for small molecules to become clinically relevant. Protein kinases are attractive cellular targets; however,
Vihinen, Mauno   +8 more
core   +2 more sources

Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL

open access: yesHematology/Oncology and Stem Cell Therapy, 2023
BTK (Bruton's tyrosine kinase) inhibitors are highly effective front-line therapy for CLL (chronic lymphocytic leukemia) due to high response rates and prolonged progression-free survival, even in patients with high-risk disease features.
Theo Sottero, Farrukh T. Awan
doaj   +1 more source

How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists

open access: yesCurrent Oncology, 2023
The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents.
Shannon Nixon   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy